Lumanity | PHARMO
PART OF LUMANITY

Real World Evidence in Amyloidosis

Lumanity and The PHARMO Institute delivers research insights into amyloidosis and its hard-to-identify subtypes.

Lack of international consensus on classification, coupled with limited specificity of ICD-10 codes pose challenges to a clinically validated cohort of amyloidosis patients.

We invite you to test the following research objectives with us:

Clinical subtypes of amyloidosis

Systematic amyloidosis

- Light chain (AL)
- Amyloid (AA)

Transthyretin amyloidosis (TTR)

- Cardiomyopathy (ATTR-CM)
- Peripheral neuropathy (ATTR-PN)
- Hereditary ATTR (hATTR)
- Wild-type (ATTR-wt)

Burden of illness

- Clinical characteristics
- Comorbidities (e.g., hypertension, atrial fibrillation, cardiac/vascular implant or graft presence, heart failure, chronic ischemic heart disease, lipoprotein metabolism disorder)
- Malignancy, pathology
- Multi-setting healthcare resource use (in-patient & out-patient drug utilization, hospital admissions, specialist visit [e.g., cardiologist, neurologist], general practitioner long-term follow-up)
- Mortality

Early identification of disease

- Risk & prognostic factors
- Disease prediction / algorithm development

What makes us different

High patient counts in amyloidosis

>10,000 patients with an amyloidosis-related hospital admission or ambulatory consultation

Data linkages enable cohort validation

- Biopsy results and gene sequences (from the Pathology Registry)
- Blood test results (e.g., troponin T, NT pro-BNP) (from clinical labs)
- Immunochemistry (e.g., immunoglobulins) (from clinical labs).
- Unstructured free text notes (from general practitioner data)

A unique, longitudinal, and clinically rich dataset

- 2002 onwards (20+ years)
- Ability to follow through multiple healthcare settings
- Data regularly updated and expanded to include new patients and follow-up information

About PHARMO

The PHARMO Institute is a **global leader** in drug safety and outcomes research

The Netherlands has an excellent healthcare system and is a major hub for clinical trials

Dutch data is **representative of Western Europe** and can be used in global studies as a robust proxy or complement to EU-5

PHARMO maintains an extensive network of data partners across NA and Europe. As a founding member of SIGMA Consortium, we can access diverse sources of **pan-European real world data (RWD) on >100 million patients**

Our capabilities and experience enable us to deliver on a **wide range of real world evidence (RWE) use cases**

Why choose us?

We can be counted on for service and quality. We utilize proven processes supported by technologically advanced resources to produce high-quality services, with guaranteed satisfaction.

Lumanity | PHARMO
PART OF LUMANITY

lumanity.com
contact@lumanity.com